New beta-blocker trialled

Article

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

The randomized multicentre study, in which the investigators will be masked, will segregate subjects into treatment groups receiving either 0.75% OT-730, 0.5% timolol maleate or placebo. Due to its unique chemical make-up, Othera is confident that OT-730 will not produce the systemic side effects commonly associated with beta-blockers. Indeed, during preclinical studies, OT-730 demonstrated a safety and IOP-lowering efficacy profile which was superior to that of timolol maleate.

Othera is also currently running a Phase II trial for OT-551, a small molecule to inhibit oxidative stress and inflammation due to disease, for dry age-related macular degeneration.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.